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Loss of VHL and hypoxia provokes PAX2 up-regulation in clear
cell renal cell carcinoma
Abstract
PURPOSE: The paired box gene 2, PAX2, encodes for a transcription factor that is up-regulated during
nephrogenesis and becomes silenced in mature epithelium of the glomeruli, the proximal, and distal
tubules. Reactivation of PAX2 has been frequently observed in clear cell renal cell carcinoma (ccRCC),
a tumor type characterized by loss of von Hippel-Lindau (VHL) tumor suppressor function. The
regulation of PAX2 expression in ccRCC is unknown. EXPERIMENTAL DESIGN: We applied
reporter gene assays to investigate PAX2 promoter regulation. Furthermore, PAX2 expression was
determined in ccRCC cell lines under normoxic and hypoxic condition in a VHL wild-type and mutated
background. PAX2 expression was also assessed in 831 human ccRCC and correlated with
hypoxia-inducible factor alpha (HIFalpha) and clinical parameters. RESULTS: Here, we show that both
loss of VHL protein (pVHL) function and hypoxia leads to strong PAX2 reexpression. Using luciferase
reporter gene assays, no induction was obtained in spite of six hypoxia response element motifs
identified in the promoter of PAX2. Comprehensive immunohistochemical analyses showed significant
correlations between PAX2, HIF1alpha, and HIF2alpha-target CCND1 expression patterns in ccRCC
patients. Notably, PAX2 expression was highly associated with early-stage, well-differentiated ccRCC
and, consequently, better clinical outcome (P < 0.0001 each). Additional analyses indicated that PAX2
repressor WT1 and cancer-linked hypomethylation are not important for transcriptional regulation of
PAX2 in ccRCC. CONCLUSION: We conclude that in ccRCC, PAX2 reactivation is driven by
HIF-dependent mechanisms following pVHL loss.
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Loss of VHL and Hypoxia Provokes PAX2 Up-Regulation
in Clear Cell Renal Cell Carcinoma
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Abstract Purpose: The paired box gene 2, PAX2, encodes for a transcription factor that is up-
regulated during nephrogenesis and becomes silenced in mature epithelium of the
glomeruli, the proximal, and distal tubules. Reactivation of PAX2 has been frequently
observed in clear cell renal cell carcinoma (ccRCC), a tumor type characterized by loss
of von Hippel-Lindau (VHL) tumor suppressor function. The regulation of PAX2 expres-
sion in ccRCC is unknown.
Experimental Design: We applied reporter gene assays to investigate PAX2 promoter
regulation. Furthermore, PAX2 expression was determined in ccRCC cell lines under
normoxic and hypoxic condition in a VHL wild-type and mutated background. PAX2 ex-
pression was also assessed in 831 human ccRCC and correlated with hypoxia-inducible
factor α (HIFα) and clinical parameters.
Results: Here, we show that both loss of VHL protein (pVHL) function and hypoxia leads
to strong PAX2 reexpression. Using luciferase reporter gene assays, no induction was
obtained in spite of six hypoxia response element motifs identified in the promoter of
PAX2. Comprehensive immunohistochemical analyses showed significant correlations
between PAX2, HIF1α, and HIF2α—target CCND1 expression patterns in ccRCC pa-
tients. Notably, PAX2 expression was highly associated with early-stage, well-differen-
tiated ccRCC and, consequently, better clinical outcome (P < 0.0001 each). Additional
analyses indicated that PAX2 repressor WT1 and cancer-linked hypomethylation are
not important for transcriptional regulation of PAX2 in ccRCC.
Conclusion: We conclude that in ccRCC, PAX2 reactivation is driven by HIF-dependent
mechanisms following pVHL loss.
The majority of sporadic clear cell renal cell carcinoma (ccRCC)
is characterized by von Hippel-Lindau (VHL) gene mutations
that dysregulate the function of the VHL protein (pVHL; ref. 1).
pVHL acts as a multipurpose adaptor protein, which is part of
distinct multiprotein complexes controlling microtubule-based
processes, extracellular matrix assembly, and transcription regu-
latory pathways (2). The best-described function of pVHL as
transcriptional regulator is its ability of targeting the α subunits
of HIF for ubiquitin-mediated proteolysis via E3 ubiquitin pro-
tein ligase complex (3, 4). In ccRCC, loss of pVHL function pro-
vokes cell invasion, angiogenesis, glucose metabolism, and
survival but also destabilization ofmicrotubules and primary cil-
ia (5–9). An essential part of these processes is evoked by HIF-
mediated gene expression programs. Stabilization of HIF due
to VHLmutation considerably contributes to both ccRCC forma-
tion and progression.
More than 100 putative HIF target genes either indirectly ac-
tivated or directly regulated by a functional HIF binding site
have been identified (10). Common and contrasting properties
of the functions of the two isoforms HIF1α and HIF2α have
been described in different cancer cell types (11, 12). Interest-
ingly, HIFα isoforms displayed suppressive interactions in RCC
cells, with enhanced expression of HIF2α suppressing HIF1α
and vice versa (11). Although binding the same DNA motif,
it is yet unclear how HIF1α and HIF2α are able to differently
regulate common and unique target genes. The identification
of additional yet unknown HIF target genes would contribute
to a better understanding of the common and different roles
of HIF1α and HIF2α in ccRCC.
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The paired box gene 2, also termed PAX2, is a member of the
PAX gene family of developmental transcription factors that is
abundantly expressed in the developing eyes, ears, central ner-
vous, and urogenital systems (13). Induction of nephrogenesis
by the ureter is accompanied by up-regulation of PAX2 fol-
lowed by cell proliferation of the ureteric bud and transactiva-
tion of the promoter of the tumor suppressor gene WT1, which
leads to repression of PAX2 and the differentiation of the ne-
phrogenic mesenchyme (14). In addition to fetal tissues, high
levels of PAX2 expression were also observed in several human
tumors, including leukemia; breast, ovarian, endometrium, and
prostate cancer; Wilms' tumor; as well as ccRCC (15).
Little is known about the regulatory mechanisms leading to
the activation of PAX2 expression in ccRCC. Two transcription
start sites within the PAX2 promoter have been reported in a
Wilms' tumor sample (16). In endometrial carcinoma, PAX2
was shown to be activated by hypomethylation of its promoter
in an estrogen- and tamoxifen-dependent manner (17). Our se-
quence analysis of the PAX2 promoter region revealed six puta-
tive hypoxia response elements (HRE). As PAX2 is absent in
normal renal tubular epithelial cells but expressed in 88% to
100% of ccRCC (18–20), the up-regulation of PAX2 might be
caused by either cancer-linked hypomethylation orHIF stabiliza-
tion as a consequence of pVHL loss of function. In this study, we
investigated both the methylation status of the PAX2 promoter
and the regulatory role of HIF for PAX2 expression in ccRCC.
Materials and Methods
Analysis of the PAX2 promoter. Computer-assisted PAX2 promoter
analysis was done using Genomatix Gene2Promoter software3 and
EMBL sequence AF515729 to identify potential HREs. CpG islands were
detected using the CpG Island Searcher program.4
Methylation-specific PCR. In total, 20 frozen ccRCC tissue samples
and their corresponding normal kidney samples were analyzed. Ge-
nomic DNA was extracted using Qiagen Blood and Tissue kit and bisul-
fite converted using EZ DNA Methylation kit (Zymo Research). The
same methylation-specific primers for the PAX2 promoter were used
as published by Wu et al. (17). DNA from a subset of patients treated
with SssI methyltransferase (New England Biolabs) was used as a pos-
itive control for methylated alleles.
Cell culture. The ccRCC-derived cell line 786-O and the human em-
bryonic kidney cell line HEK-293 were supplied by the American Type
Culture Collection. Stable transfectant of 786-O reexpressing pVHL30
was generated as mentioned (21). The RCC4 cell line and its
corresponding transfectant RCC4 VHL reexpressing wild-type pVHL30
were created as described (5, 7). Human renal proximal tubular epithe-
lial cell line HK-2 was provided by R. Wüthrich (Clinic for Nephrology,
Department of Internal Medicine, University Hospital Zurich, Zurich,
Switzerland). RCC4, HEK-293, and HK-2 were cultured as reported pre-
viously (22). Hypoxic experiments with HK-2 and RCC4 were done for
16 h at 1% oxygen using an Invivo2 400 hypoxia workstation (Biotrace
International). Dimethyloxallyl glycine (DMOG; Cayman Chemical)
treatment in HK-2 and HEK-293 cells was done at 1 mmol/L over
24 h. Cobalt chloride (CoCl2; Sigma) treatment in 786-O and 786-O
pVHL30 was done at 0.5 mmol/L over 24 h.
HIF2α short hairpin RNA constructs and lentiviral infections. Expres-
sion vectors encoding short hairpin RNA sequences targeting human
HIF2α were purchased from Sigma (shHIF2α #1, clone ID
NM_001430.x-517s1c1 and shHIF2α #4, clone ID NM_001430.
x-1694s1c1, respectively). Viral particles were produced using ViraPower
lentiviral expression system according to the manufacturer's instructions
(Invitrogen). Briefly, 786-O and 786-O pVHL30 cells were infected with
lentiviral particles of either shHIF2α #1 or shHIF2α #4 constructs and
pool of clones was derived by puromycin selection (4 μg/mL). Pools of
clones were analyzed for effective HIF2α knockdown by quantitative re-
verse transcription-PCR and anti-HIF2α immunoblotting.
Tissue specimen and tissue microarray construction. We used tissue
microarrays (TMA) comprising 831 nephrectomy ccRCC collected from
the University Hospital Zurich, the Kantonsspital St. Gallen (St. Gallen,
Switzerland), and the University Hospital of Basel (Basel, Switzerland).
All ccRCC samples were histologically reviewed by one pathologist
(H.M.) and selected for the study based on H&E-stained tissue sections.
For all cohorts, a RCC TMA was constructed as previously described
(23). This study was approved by the local commission of ethics (ref-
erence number StV 38-2005). Clinical information was obtained for
519 cases. The mean age of patients was 62.7 (15-88) and mean fol-
low-up was 51.9 mo (0.1-229). Tumors were graded according to the
Thoenes grading system and histologically classified according to the
WHO classification (24). There were 163 grade 1 (20%), 415 grade 2
(50%), 248 grade 3 (30%), 161 pT1 (20%), 223 pT2 (27%), 412 pT3
(50.5%), and 20 pT4 (2.5%) tumors.
Western blot analysis. Whole-cell lysates were prepared using radio-
immunoprecipitation assay buffer (Sigma) containing complete prote-
ase inhibitor cocktail (Roche). Homogenization was done with a tissue
lyser (Qiagen) for 4 min at 20 Hz. Lysates were centrifuged for 10 min
(2,500 × g, 4°C). Protein concentration of the supernatant was deter-
mined by the bicinchoninic acid assay (Pierce) with bovine serum albu-
min as a standard. Equivalent amounts of protein (15-50 μg) were
separated on NuPAGE Bis-Tris Gels with a gradient of 4% to 12% (Invi-
trogen) and transferred to nitrocellulose membranes (Schleicher/
Schuell). Membranes were blocked in TBS-Tween 20 containing 5%
(w/v) nonfat dry milk for 1 h at room temperature. After washing in
TBS-Tween 20, membranes were incubated overnight at 4°C using the
following primary antibodies: rabbit polyclonal anti-PAX2 (clone C-
RX2; 1:1,000; Invitrogen), rabbit polyclonal anti-HIF2α (clone NB100-
122; 1:1,000; Novus Biologicals), mouse monoclonal lamin A/C
(1:3,000; BD Biosciences), and mouse monoclonal anti–β-actin (clone
MAB1501; 1:10,000; Chemicon International). After washing with TBS-
Tween 20, the membranes were incubated at room temperature with
Translational Relevance
In clear cell renal cell carcinoma (ccRCC), the acti-
vation of hypoxia-inducible factor α (HIFα)–mediated
transcriptional programs is caused by loss of func-
tion of the von Hippel-Lindau protein (pVHL). The
identification of yet unknown HIF target genes will
improve our understanding of the biological conse-
quences of a deregulated VHL/HIF pathway in ccRCC,
a prerequisite for the development of therapeutic an-
ticancer strategies. The transcription factor PAX2 has
been recently suggested as a potential therapeutic
target gene in renal cancer. We have found that
PAX2 is negatively regulated by pVHL and is induced
by hypoxia. Furthermore, we observed a significant
correlation between PAX2 and HIFα in ccRCC pa-
tients. Notably, PAX2 expression correlated with
tumor grade and stage in ccRCC. This is the first
study showing HIF-dependent up-regulation of the
cancer target gene PAX2 as a consequence of VHL
loss of function in ccRCC cell lines and human tumor
tissues.
3 http://www.genomatix.de
4 http://www.cpgislands.com
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horseradish peroxidase–conjugated secondary antibody rabbit anti-
mouse (1:3,000; Dako) or goat anti-rabbit (1:3,000; Dako). The pro-
tein-antibody complexes were detected by enhanced chemiluminescence
(Amersham).
Reporter gene assay. The PAX2 promoter (16) was obtained by PCR
amplification of genomic DNA using the oligonucleotide primers 5′-
ATGCACTAGTCCTGCAGGAGGAGGAGAGG-3′ and 5′-ATGCGA-
TATCCTCCCGGTGTGTGTCTCTCT-3′. PCR products were sequenced
using the ABI Prism 3100 Genetic analyzer (Applied Biosystems).
pGLPAX2prom was constructed by insertion of a 3.47-kb SpeI-EcoRV
fragment from the human PAX2 promoter into the NheI-EcoRV sites of
a pGL4.10 firefly luciferase reporter plasmid (Promega). For transcrip-
tional transactivation experiments, HEK-293 and HK-2 cells were
transfected with 1 μg of pGLPAX2prom reporter plasmid along with
100 ng of pGL4.74 Renilla luciferase reporter plasmid (Promega) in
24-well plates using FuGene 6 reagent (Roche Molecular Biochem-
icals). pGl3P2P(607bp) vectors are 5′-truncated versions of the previ-
ously published pGl3b(1454/3172)P2P plasmids containing the wild-
type or mutated HRE of the human PHD2 promoter (provided by
Dr. Daniel Stiehl, University of Zurich, Zurich, Switzerland). pGLTf
are pGL3prom vectors (Promega) that carry either wild-type HRE
(HREww) or antisense sequence (ERHmm) derived from transferrin
enhancer (25). These vectors served as positive and negative controls
for HIFα activity. After transfection, cells were incubated with and
without DMOG (1 mmol/L) for 24 h. Luciferase activity was mea-
sured after cell lysis using the dual-luciferase reporter assay system
(Promega). Relative luciferase units were determined by dividing the
luciferase activity of the pGL4.10 reporter constructs by that of the
pGL4.74 control reporter.
Immunohistochemistry. TMA sections (2.5 μm) were transferred to
glass slides followed by immunohistochemical analysis according to
the Ventana automat protocols. The same antibodies used for Western
blot analysis were applied for detection of PAX2 (dilution, 1:500),
HIF1α (1:500; Abcam Ltd.), CCND1 (clone SP4, 1:40; Labvision),
and WT1 (clone 6F-H2, 1:50; Dako). Analysis was done with a Leitz
Aristoplan microscope (Leica). Pictures of ccRCC specimens were taken
with the digital camera KY-070 (JVC). Tumors were considered PAX2,
HIF1α, CCND1, or WT1 positive if >5% of tumor cells showed nuclear
expression. All TMAs were analyzed by one pathologist (P.J.W.).
Statistical analysis. Contingency table analysis, χ2 tests, Kaplan-
Meier curve, and log-rank tests for evaluating correlations between
PAX2, HIF1α, and CCND1 expression as well as clinical parameters
were calculated using StatView 5.0 (SAS).
Results
HRE sequences and CpG islands in the PAX2 promoter.
Our in silico sequence analyses revealed six potential HREs
Fig. 1. PAX2 expression pattern in 16 sporadic ccRCC patients. A to H, tumors with wild-type VHL. I to P, tumors with mutated VHL.
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(gcgtg) in the 3,476-bp PAX2 promoter region (3,810-3,806,
2,536-2,532, 1,996-1,992, 1,801-1,797, 1,387-1,383, and
1,312-1,308 bp 5′ of the ATG start codon; see Supplementary
Fig. S1A for details). We also detected three putative CpG islands
with a minimal length of 100 bp in the 4,158-bp region (pro-
moter and 5′-untranslated region) upstream of the ATG start
codon (Supplementary Fig. S1B).
PAX2 expression in VHL mutated and wild-type ccRCC. The
presence of several HRE motifs in the PAX2 promoter region
prompted us to investigate whether PAX2 expression is HIF
dependent and regulated by pVHL in ccRCC. Here, we used a
small TMA consisting of 16 ccRCC (8 with wild-type VHL and
8 with VHL frameshift mutations). PAX2 was expressed only
weakly in two wild-type VHL patients, whereas moderate and
strong nuclear PAX2 staining was seen in six of eight VHL
mutated ccRCC (Fig. 1).
PAX2 expression under hypoxia. To test whether PAX2
expression is HIF dependent, VHL-positive renal proximal tu-
bular cells HK-2 were subjected to hypoxia. HK-2 cells do not
express PAX2 at normoxic condition. PAX2 protein level was
strongly up-regulated after 16 hours of hypoxia, suggesting a
HIF-dependent induction of PAX2 (Fig. 2A).
PAX2 expression under hypoxia in VHL-positive and VHL-
negative tumor cells. We investigated whether the up-regulation
of PAX2 levels under hypoxic conditions is VHL dependent. To
this end, we used the ccRCC cell l ine RCC4 and its
corresponding transfectant RCC4 VHL reexpressing wild-type
pVHL30. Figure 2B shows the PAX2 transcript levels in RCC4
and RCC4 VHL grown under normoxic and hypoxic conditions.
The PAX2 transcript level remains stable under hypoxia in
RCC4 cells. In RCC4 VHL, PAX2 was drastically reduced under
normoxia, whereas hypoxia led to a 52-fold increase of the
PAX2 level (Fig. 2B), which is comparable with that of RCC4
cells under hypoxic condition. The PAX2 mRNA expression
data could further be confirmed with immunoblotting data
(Fig. 2C), although induction of PAX2 expression under hypox-
ia in RCC4 VHL cells is somewhat weaker than observed on the
mRNA level. We also determined the PAX2 expression level in
786-O and 786-O pVHL30 cell lines. Here, we observed a higher
PAX2 level in 786-O cells compared with 786-O pVHL30 under
normoxic condition (Fig. 2C). Similar to RCC4 VHL cells, an
increase of PAX2 level was observed under hypoxia in 786-O
pVHL30 cells (Fig. 2C). This expression was comparable with
that of VHL-negative 786-O cells, suggesting again a role for
pVHL in regulating PAX2 expression via HIF. In addition, si-
lencing of HIF2α by RNA interference leads to a reduction of
PAX2 in these cell lines (Fig. 2D). To further evaluate whether
the VHL/HIF signaling pathway is involved in PAX2 regulation,
786-O pVHL30 cells were treated with CoCl2, which resulted in
an up-regulation of both HIF2α and PAX2 (Fig. 2E), again
confirming HIF-dependent regulation of PAX2.
PAX2 promoter reporter gene assays. Luciferase reporter as-
says were done to verify the functionality of the putative HREs
in the promoter region of PAX2. For this purpose, a PAX2 pro-
moter DNA fragment was inserted upstream of a promoterless
luciferase reporter gene vector. Following transient transfection,
HEK-293 cells were treated with and without DMOG. DMOG
is a prolyl hydroxylase inhibitor resulting in HIFα stabilization
Fig. 2. A, Western blot analysis of HK-2 cells grown under normoxia (N) and hypoxia (H). β-Actin was used as a loading control. B, relative PAX2 mRNA
expression level of RCC4 and RCC4 VHL cells under normoxic and hypoxic conditions as measured by quantitative real-time PCR. Transcript level at
normoxia was set to 1. Columns, mean of three independent experiments; bars, SE. C, PAX2 protein expression in RCC4 and RCC4 VHL cells under normoxia
and hypoxia. D, PAX2 protein level in the ccRCC-derived cell lines 786-O and 786-O pVHL30 under normoxia and hypoxia and with silenced HIF2α
background. Lamin A/C was used as loading control. E, PAX2 protein level in 786-O pVHL30 subjected to CoCl2 treatment.
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and increased HIF activity. The reporter activity of the vector
containing the whole PAX2 promoter was unchanged in
HEK-293 cells after treatment with DMOG compared with un-
treated cells (Fig. 3A). Specificity of DMOG-induced HIF activ-
ity was shown by using reporter vectors comprising wild-type
or mutated HREs of the HIF target prolyl hydroxylase 2 (P2P).
A 2.6-fold induction of the P2P wild-type reporter indicated
the activation of the HIF pathway after DMOG treatment.
No increase of luciferase activity was measured in the vector con-
taining the mutated HRE of P2P (Fig. 3A). Similar experiments
were done for HK-2 cells. Here, the integrity of the luciferase
reporter gene assay was tested by measuring the activity of
wild-type and mutated transferrin promoter pGLTfHREww and
pGLTfERHmm, respectively. PAX2 promoter (pGLPAX2prom)
activity remained unchanged on DMOG treatment in HK-2 cells
(Fig. 3B). These results show that the identified putative HRE in
the PAX2 promoter region is not sufficient for the induction of
PAX2 expression by HIF in HEK-293 and HK-2 cells.
Correlation of PAX2 expression with HIF1α and HIF2α
expression in ccRCC tissues. The results from the in vitro experi-
ments motivated us to further investigate PAX2 expression in
relation to HIF expression. To this end, we analyzed TMAs com-
prising 831 ccRCC to evaluate the correlation between PAX2
and HIF1α expression. Of 294 PAX2-positive tumors, 222
(75.5%) also expressed HIF1α (P < 0.0001). Due to technical
problems with HIF2α antibody on immunohistochemistry,
we used the HIF2α target CCND1 as readout for HIF2α. Of
310 PAX2-expressing tumors, 253 (81.6%) stained also positive
for CCND1 (P < 0.0001).
Correlation between PAX2 expression and tumor grade, stage,
and survival. We next investigated the relations of PAX2 expres-
sion to clinicopathologic parameters in ccRCC. We observed a
strong differentiation grade-dependent PAX2 expression in
ccRCC. One hundred three of 155 (66.5%) grade 1 tumors ex-
pressed PAX2, whereas in grade 3 tumors 54 of 228 (23.7%)
were PAX2 positive (Table 1). We also observed decreasing
PAX2 expression with increasing tumor stage. For example, only
2.7% of pT3 and pT4 tumors show strong PAX2 staining inten-
sity (Table 1). Consequently, there was also a significant corre-
lation between PAX2 level and overall survival in ccRCC
patients (Fig. 4). Patients with PAX2 expression had a better
prognosis than patients with PAX2-negative tumors. However,
the association between PAX2 expression and clinical outcome
was not independent from tumor grade and tumor stage (data
not shown).
PAX2 expression in ccRCC is not dependent on hypomethylation.
Several ccRCC (24.5%) showed no correlation between PAX2
and HIF1α expression, suggesting other mechanisms for PAX2
up-regulation in these cancers. The existence of CpG islands in
the promoter region of PAX2 led us to investigate whether
PAX2 expression in ccRCC might be controlled by epigenetic me-
chanisms. We assessed the methylation status of PAX2 promoter
by methylation-specific PCR. In total, we analyzed 20 ccRCC
and their patient-matched normal kidney tissue. In all normal
and tumor samples, PAX2 promoter was unmethylated (exam-
ples are shown in Fig. 5A). In vitro methylated DNA from a pa-
tient subset served as a positive control for methylated alleles
(Fig. 5B).
Fig. 3. HIF responsiveness of the PAX2 promoter region. Luciferase reporter gene activity following transient transfection with or without HIF induction
by DMOG for 24 h of HEK-293 (A) and HK-2 (B) cells with luciferase expression plasmids containing the 3.5-kb PAX2 promoter. A cotransfected Renilla
luciferase expression vector served as internal control for transfection efficiency. Fold induction is relative to reporter gene activities of HEK-293 cells without
DMOG treatment. Positive and negative controls are described in Materials and Methods. Columns, mean; bars, SD.
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Discussion
In this study, we investigated the molecular mechanisms
leading to PAX2 up-regulation in ccRCC. Detailed sequence
analysis of the PAX2 promoter unmasked HREs and CpG is-
lands, suggesting that the up-regulation of PAX2 in ccRCC is
driven by HIF and/or cancer-linked hypomethylation. Our
in vitro analysis revealed that in ccRCC, the activation of tran-
scription regulator PAX2 is induced by hypoxia and depends on
the functional integrity of pVHL. An additional TMA-based
analysis of 831 ccRCC showed that PAX2 is preferentially ex-
pressed in highly differentiated early-stage tumors. PAX2 ex-
pression was significantly correlated with the expression of
HIF1α and HIF2α target CCND1, indicating that PAX2 activa-
tion is mainly regulated by HIF.
The identification of six putative HRE consensus sequences
in the PAX2 promoter prompted us to analyze PAX2 expres-
sion in pVHL-negative and pVHL-transfected RCC4 cells and
normal pVHL-positive HK-2 and HEK-293 cells. Up-regulation
of PAX2 was seen in RCC4 but not in pVHL-positive transfec-
tant and HK-2. Increased expression of PAX2 was determined
in DMOG-treated HK-2 cells and pVHL-expressing RCC4. In
wild-type RCC4, PAX2 protein expression levels remained sta-
ble under normoxia and hypoxia. Luciferase reporter gene as-
says were applied to confirm the HIF-induced activation of the
PAX2 promoter. These experiments failed to show an in-
creased activity of a reporter vector containing the PAX2 pro-
moter after stabilization of HIF. Therefore, our in vitro data
imply molecular mechanisms for PAX2 expression in ccRCC,
which necessitate other tissue-specific factors in addition to
HIF. Given the nature of HRE as an enhancer, it might also
be possible that relevant HREs outside the PAX2 promoter
are responsible for HIF induction. HIF-independent activation
of genes under hypoxia has been described, for example, for
mammalian target of rapamycin (26) and DNASE1 (27). Tran-
scriptional response to PAX2 might also be mediated by yet
unknown cis-acting elements located outside the PAX2 pro-
moter. Such enhancer elements have been identified 3′ to
the human erythropoietin gene (28).
We further confirmed our in vitro results that showed the in-
fluence of pVHL on PAX2 expression by using a small TMA with
arrayed normal renal tissues, VHL wild-type ccRCC, and ccRCC
with frameshift mutations (1, 29). As expected, all normal tis-
sues were PAX2 negative, whereas only 2 of 8 VHL wild-type
ccRCC but 6 of 8 (75%) VHL mutated tumors expressed
PAX2. PAX2 expression correlated with the presence of VHL
“loss-of-function” mutations (1, 29), which highly likely cause
pVHL loss and stabilize HIF.
PAX2 expression has previously been described in ccRCC
cell lines and tissues (18–20, 30). In these studies, relative
small numbers of ccRCC were analyzed and the frequencies
of PAX2-positive tumors varied between 88% and 100%. We
significantly extended these studies using TMAs that
contained 831 ccRCC specimens. Here, we showed that
PAX2 was expressed predominantly in early-stage and low-
grade cancers. This observation suggests that the up-regula-
tion of PAX2 represents an early step in ccRCC development.
To test whether PAX2 activation is dependent on HIF, we an-
alyzed the expression of HIF1α and HIF2α target CCND1 on
our ccRCC TMAs. The significant correlation between PAX2,
HIF1α, and CCND1 expression strongly argues for a direct
or indirect regulatory effect of both HIF1α and HIF2α on
PAX2 transcription.
The ability to transcriptionally repress the tumor suppressor
p53 (31) and its joint action with CCND1 makes PAX2 an im-
portant promoter of cell proliferation, which might be regarded
as one of the most critical steps toward ccRCC development. In
humans with kidney malformations, including polycystic kid-
ney disease and juvenile cystic kidneys, it was shown that
PAX2 is abundantly present in cystic and hyperproliferative ep-
ithelial cells (32, 33). Reduced PAX2 gene dosage inhibited sig-
nificantly renal cyst growth in mice (34). Interestingly, patients
with hereditary and sporadic ccRCC also frequently have intra-
tumoral cysts (35), which are thought to be a result of uncon-
trolled cell proliferation and represent tumor precursor lesions
Table 1. Correlation between PAX2 expression and tumor grade and stage
Tumor PAX2 intensity, n (%) PAX2-expressing cells, n (%)
Negative Weak Moderate Strong P 0-5% 6-50% >50% P
Grade 1 52 (33.5) 44 (28.4) 20 (12.9) 39 (25.2) <0.001 52 (33.5) 18 (11.6) 85 (54.8) <0.001
Grade 2 233 (59.4) 102 (26.0) 40 (10.2) 17 (4.3) 233 (59.4) 46 (11.7) 113 (28.8)
Grade 3 174 (76.3) 36 (15.8) 12 (5.3) 6 (2.6) 174 (76.3) 16 (7.0) 38 (16.7)
pT1,2 178 (49.4) 93 (25.8) 40 (11.1) 49 (13.6) <0.001 178 (49.4) 38 (10.6) 144 (40.0) <0.001
pT3,4 278 (68.5) 86 (21.2) 31 (7.6) 11 (2.7) 278 (68.5) 41 (10.1) 87 (21.4)
NOTE: Please note combined pT stages (pT1,2 and pT3,4).
Fig. 4. PAX2 expression and overall survival in ccRCC patients.
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(36, 37). It is therefore tempting to speculate that PAX2 is the
driving force for cyst formation in ccRCC.
As PAX2 is silenced in normal renal tubular epithelial cells,
reactivated in early ccRCC stage, and down-regulated during tu-
mor progression, it seems obvious that HIF is not the only fac-
tor being responsible for PAX2 expression. Our finding that
PAX2 and HIF positivity was not correlated in 24.5% of the tu-
mors suggests other molecular factors that regulate PAX2 tran-
scription. We therefore looked for additional possible
mechanisms that would explain at least in part the discrepant
PAX2 expression patterns. As it was shown in endometrial can-
cer, activation of PAX2 is associated with hypomethylation of
its promoter (17). Using the same protocols, hypermethylation
of PAX2 promoter was seen neither in normal renal tissue nor
in late-stage ccRCC, suggesting that the transcriptional regula-
tion of PAX2 differs between endometrial cancer and ccRCC.
Previous studies showed that PAX2 is repressed byWT1 during
normal kidney development (14) and that PAX2 is up-regulated
in Wilms' tumor (38). Because the frequencies reported for WT1
expression in RCC are rather inconsistent (39–41), we compared
WT1 and PAX2 expression on our TMAs. None of the normal re-
nal tissues and only 5% of the ccRCC stained weakly for WT1, ex-
cluding a key role of WT1 as transcriptional repressor of PAX2 in
ccRCC (data not shown). Considerable genetic heterogeneity be-
tweenprimary RCCandmetastases has been previously described
and suggests the existence of yet unknown genetic factors contrib-
uting to PAX2 down-regulation during the metastatic process.
In summary, our in vitro and in vivo data show that in ccRCC
PAX2 is a hypoxia-regulated gene negatively controlled by
pVHL. The frequent expression of PAX2 in ccRCC and its highly
significant correlation with better clinical outcome together with
its oncogenic function might validate PAX2 as appropriate target
for renal cancer therapy. In normal kidney cells and fetal kidney
explants, PAX2 conferred resistance to cisplatin-induced apopto-
sis (42). Xenografts of shPAX2-treated ACHN cell line in nude
mice confirmed that the tumors were more responsive to cisplat-
in therapy than PAX2-positive control cells. These results might
implicate PAX2 as potential predictive marker in ccRCC, espe-
cially for those patients with organ-confined ccRCC that will de-
velop metastasis and succumb to their disease.
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